SPECTAbrain: Screening Patients With Brain Tumors for Efficient Clinical Trial Access

The SPECTAbrain protocol describes a structure for screening patients with brain tumors to efficiently allocate eligible patients in relevant therapeutic biomarker-driven clinical trials. Efficiency is promoted through the creation of a clinical database of brain tumor patients and the respective human biological material biobank for molecular characterization. The main objectives are to: * Allocate patients to clinical trials according to the clinical characteristics and molecular profile of their tumor; * Identify or validate new molecularly defined subgroups of tumors; * Investigate the prevalence of novel biomarkers to plan future clinical trials; * Enable exploratory/future research; * Facilitate establishment of quality-assured and validated tests for Central Nervous System (CNS) tumor biomarkers;